Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine liposome injection for enhanced recovery after open ovarian cancer surgery
ChiCTR2400083026Phase 4Not yet recruiting
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ovarian cancer comparing Bupivacaine Liposomal Group with Ropivacaine Group (2 arms). Primary endpoints: Systolic blood pressure, Diastolic blood pressure and 12 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
bupivacaineropivacaine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR2400083026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083026.